Changes in Renal Function in @entity1 With XXXX : An Analysis From the RE-LY Trial.

@entity1 @entity6 @entity2067 @entity14534 @entity955 @entity1011 @entity729 @entity1229
BACKGROUND: @entity2067 -dependent factors protect against @entity729 , and @entity2067 antagonists may be associated with a decreased glomerular filtration rate (GFR). OBJECTIVES: This study analyzed changes in GFR during long-term treatment with @entity1229 or @entity14534 (DE) in @entity1 enrolled in the RE-LY (Randomized Evaluation of Long Term Anticoagulation Therapy) trial. METHODS: Of the 18,113 @entity1 in the RE-LY study randomized to receive DE (110 mg or 150 mg twice daily) or @entity1229 , 16,490 @entity1 with @entity955 had @entity1011 values measured at baseline and at least 1 follow-up visit. Changes in GFR for up to 30 months were evaluated. RESULTS: GFR declined in all treatment groups. After an average of 30 months, the mean    SE decline in GFR was significantly greater with @entity1229 (-3.68    0.24 ml/min) compared with DE 110 mg (-2.57    0.24 ml/min; p  = 0.0009 vs. @entity1229 ) and DE 150 mg (-2.46    0.23 ml/min; p  = 0.0002 vs. @entity1229 ). A decrease in GFR >25% was less likely with DE 110 mg (hazard ratio: 0.81 [95% confidence interval: 0.69 to 0.96]; p  = 0.017) or DE 150 mg (hazard ratio: 0.79 [95% confidence interval: 0.68 to 0.93]; p  =  0.0056) than with @entity1229 in the observation period >18 months. @entity1 with poor international normalized ratio control (i.e., time in therapeutic range  <65%) exhibited a faster decline in GFR. A more pronounced decline in GFR was associated with previous @entity1229 use and with the presence of @entity6 . CONCLUSIONS: @entity1 with @entity955 receiving oral anticoagulation exhibited a decline in renal function that was greater in those taking @entity1229 versus DE, and it was amplified by @entity6 and previous @entity2067 antagonist use. (Randomized Evaluation of Long Term Anticoagulant Therapy [RE-LY] With @entity14534 ; NCT00262600).
